
Remegen And Santen Enter Into Exclusive Licensing Agreement For Ophthalmic Innovative Drug RC28-E In Greater China And ...
(MENAFN- PR Newswire) YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: SH/09995, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen …